Johnson Financial Group Inc. Buys 4,239 Shares of Gilead Sciences, Inc. $GILD

Johnson Financial Group Inc. boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 23.0% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,645 shares of the biopharmaceutical company’s stock after acquiring an additional 4,239 shares during the period. Johnson Financial Group Inc.’s holdings in Gilead Sciences were worth $2,511,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of GILD. Rothschild Investment LLC lifted its stake in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock valued at $503,000 after buying an additional 84 shares in the last quarter. Archer Investment Corp raised its holdings in Gilead Sciences by 1.2% during the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 87 shares during the period. EPG Wealth Management LLC lifted its position in shares of Gilead Sciences by 2.0% in the second quarter. EPG Wealth Management LLC now owns 4,627 shares of the biopharmaceutical company’s stock valued at $513,000 after acquiring an additional 89 shares in the last quarter. Southland Equity Partners LLC boosted its stake in shares of Gilead Sciences by 2.9% in the second quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock worth $364,000 after acquiring an additional 92 shares during the period. Finally, Putney Financial Group LLC grew its position in shares of Gilead Sciences by 53.4% during the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the sale, the insider owned 107,193 shares in the company, valued at approximately $13,491,310.98. This represents a 20.71% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 115,146 shares of company stock valued at $14,012,141 over the last quarter. Company insiders own 0.27% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GILD shares. Citigroup boosted their price target on Gilead Sciences from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Wednesday, October 8th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a report on Friday, October 31st. Argus upped their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Truist Financial began coverage on shares of Gilead Sciences in a research note on Monday. They issued a “buy” rating and a $140.00 price target on the stock. Finally, Morgan Stanley increased their price objective on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Price Performance

GILD stock opened at $127.51 on Thursday. Gilead Sciences, Inc. has a 52 week low of $88.57 and a 52 week high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a fifty day simple moving average of $119.36 and a two-hundred day simple moving average of $114.25. The firm has a market capitalization of $158.20 billion, a P/E ratio of 25.40, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. The firm had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business’s quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be given a dividend of $0.79 per share. The ex-dividend date is Monday, December 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.5%. Gilead Sciences’s dividend payout ratio is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.